Prenetics Global Limited
HealthcareNASDAQ:PRE · NASDAQ Global Market
+$0.94 today
Vol 0.35M · Avg 0.22M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-21.6%
avg -34.5%
ROIC
-21.5%
avg -38.1%
ROA
-18.5%
avg -44.8%
Analysis
ROA is currently the strongest return metric at -18.5% versus its period average of -44.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Samantha Kwok | Chief of Staff to Group Chief Executive Officer & Vice President of People & Operations | — | — | — | — | — |
James DiNicolantonio | Chief Nutrition Officer, Member of Scientific & Medical Advisory Board | — | — | — | — | — |
Senthil Sundaram | Chief Clinical Officer | — | — | 52 | — | — |
Brian J. Rosin | Chief Financial Officer | — | — | — | — | — |
Chi Hung Tzang | Co-Founder & Chief Scientific Officer | — | — | 51 | — | — |
Hoi Chun Lo | Chief Financial Officer | — | — | 40 | $597,930.00 | 3.52% |
David Eric Vanderveen | President of Americas | — | — | 57 | $38,305.00 | 0.23% |
Joel Neoh | Chief Consumer Officer | — | — | 42 | — | — |
Sheng Wu Yeung | Co-Founder, Chairperson & Chief Executive Officer | — | — | 47 | $933,380.00 | 5.49% |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | -30.6% | +93.8% (4yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -30.6% over three years. Forward estimates point to Revenue at +93.8% (4yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
OraSure Technologies, Inc.
NASDAQ:OSUR
$287.79M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Profound Medical Corp.
NASDAQ:PROF
$200.47M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$150.58M
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
$142.92M
MaxCyte, Inc.
NASDAQ:MXCT
$119.98M
Neuronetics, Inc.
NASDAQ:STIM
$92.55M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$62.14M
Atlantic International Corp.
NASDAQ:ATLN
$47.61M
Who manages PRE?
Prenetics Global Limited (PRE) lists 9 active executives. The top listed executive is Samantha Kwok, Chief of Staff to Group Chief Executive Officer & Vice President of People & Operations.
Are PRE insiders buying or selling?
Recent insider activity shows net selling of $82.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.